PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer

PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer

IntroductionEndeavors in the molecular characterization of breast cancer opened the doors to endocrine therapies in ER+/HER2- breast cancer, increasing response rates substantially. Despite that, taxane-based neoadjuvant chemotherapy is still a cornerstone for achieving breast-conserving surgery and...

Full description

Bibliographic Details
Main Author: Gulnihal Ozcan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
breast cancer
chemoresistance
taxane-based neoadjuvant chemotherapy
predictive markers
precision medicine
bioinformatics
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1216438/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1216438/full

Similar Items